Company Profiles

driven by the PitchBook Platform

ARMGO Pharma

Description

Developer of small-molecule therapeutics designed to treat debilitating cardiac, skeletal muscular and neurological disorders. The company's small-molecule therapeutics and proprietary drugs, known as Rycals, are a new class of oral agents that repair calcium leak through the ryanodine receptor calcium-release channel (RyR), which is located on the sarcoplasmic/endoplasmic reticulum of the cell, enabling physicians to help restore the strength of muscle contraction which result in improvements in heart function and skeletal muscle strength of patients.

2004

Founded

PRIVATE

Status

11-50

Employees

Grant

Latest Deal Type

$1M

Total Amount Raised

3

Investors

Description

Developer of small-molecule therapeutics designed to treat debilitating cardiac, skeletal muscular and neurological disorders. The company's small-molecule therapeutics and proprietary drugs, known as Rycals, are a new class of oral agents that repair calcium leak through the ryanodine receptor calcium-release channel (RyR), which is located on the sarcoplasmic/endoplasmic reticulum of the cell, enabling physicians to help restore the strength of muscle contraction which result in improvements in heart function and skeletal muscle strength of patients.

Website:

www.armgo.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Therapeutic Devices

Other Industries

Drug Discovery
Other Pharmaceuticals and Biotechnology

Primary Office

777 Old Saw Mill River Road Tarry Town Tarrytown, NY 10591United States +1 (914) 425-0000
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore ARMGO Pharma's full profile, request a free trial.

    ARMGO Pharma Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    ARMGO Pharma Investors (3)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Aisling CapitalVenture CapitalMinority000 0000000 0000
    Kennedy's Disease AssociationOther000 0000000 0000
    Muscular Dystrophy AssociationVenture CapitalMinority000 0000000 0000
    Aisling Capital Venture Capital
    Kennedy's Disease Association Other
    Muscular Dystrophy Association Venture Capital

    ARMGO Pharma Executive Team (7)

    NameTitleBoard
    Seat
    Contact
    Info
    Sapan Shah Ph.DChief Executive Officer, Board Member & President
    Gene Marcantonio MDPresident & Chief Medical Officer
    Kathi LarsonChief Financial Officer
    Jairo LemaSenior Director, Information Technology
    Yael Webb Ph.DSenior Vice President, Intellectual Property, Project Manager, Clinical and Regulatory
    Sapan Shah Ph.D Chief Executive Officer, Board Member & President
    Gene Marcantonio MD President & Chief Medical Officer
    Kathi Larson Chief Financial Officer
    Jairo Lema Senior Director, Information Technology
    Yael Webb Ph.D Senior Vice President, Intellectual Property, Project Manager, Clinical and Regulatory

    ARMGO Pharma Board Members (5)

    NameRepresentingRoleSinceContact
    Info
    Alan FuchsbergSelfBoard Member000 0000
    Andrew Marks MDSelfBoard Member and Founding Scientist000 0000
    Andrew Schiff MDAisling CapitalManaging Partner000 0000
    Karen KatenSelfChairman000 0000
    Paul Marks Ph.DSelfBoard Member000 0000
    Alan Fuchsberg Board Member Self
    Andrew Marks MD Board Member and Founding Scientist Self
    Andrew Schiff MD Managing Partner Aisling Capital
    Karen Katen Chairman Self
    Paul Marks Ph.D Board Member Self
    Request full access to PitchBook